Pfizer Inc.

COVID-19

Robust Immune Response Against SARS-CoV-2 Demonstrated with Pfizer-BioNTech BNT162b2 Vaccine

Researchers conducted a three-case series study involving healthcare workers who received the Pfizer-BioNTech BNT162b2 vaccine, demonstrating a robust immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study found that the vaccine elicited a significant increase in humoral immunity, including elevated Immunoglobulin G (IgG) and Immunoglobulin A (IgA)